We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Strain-Specific Immunity Discovered for Lyme Disease

By LabMedica International staff writers
Posted on 17 Apr 2014
Print article
Image: Scanning electron micrograph of the spirochete Borrelia burgdorferi, long, slender bacteria that typically take on a coiled shape. Infection with this bacterium causes Lyme disease (Photo courtesy of Tina Carvalho).
Image: Scanning electron micrograph of the spirochete Borrelia burgdorferi, long, slender bacteria that typically take on a coiled shape. Infection with this bacterium causes Lyme disease (Photo courtesy of Tina Carvalho).
Many patients treated for early Lyme disease incur another infection in subsequent years, suggesting that previous exposure to Borrelia burgdorferi may not elicit a protective immune response.

At least 16 different strains of the Lyme disease bacterium have been shown to infect humans in the United States of America, so being bitten by a tick carrying a different strain of the disease is entirely possible.

Scientists at the University of Pennsylvania (Philadelphia, PA, USA) and their collaborators analyzed the occurrence of identical strains of B. burgdorferi in a cohort of 17 patients with multiple episodes of culture-confirmed erythema migrans. They used both multinomial probability analyses and a stochastic simulation model to evaluate whether only one or fewer of 17 patients could have identical strains of B. burgdorferi in recurrent infections due to chance alone. All analyses estimated the probability of recovering a particular strain of B. burgdorferi from a patient due to chance alone, based on empirical patient data.

The model allowed the researchers to vary assumptions such as the presence or absence of type-specific immunity, the duration of immunity, and the length of time a patient was accessible to having been bitten by a tick, or in other words, the time from the first visit to the clinic to the last visit, or from the first visit to the completion of the study.

The results of all of the simulations indicated that strain-specific immunity would need to last a minimum of four years in order to result in the suite of infections that the 17 patients acquired. When the model parameters were used with actual data from 200 patients who had been infected at least once with a known strain of B. burgdorferi, the simulation indicated that immunity lasts in the range of six to nine years. The only patient infected by the same strain twice actually had Lyme disease four times in six years, contracting K strain twice, five years apart, with an infection by a different strain in between.

The authors concluded that it is highly unlikely that only one of 17 patients would have been infected with an identical strain of B. burgdorferi in a recurrent episode of Lyme disease in the absence of strain-specific immunity. Furthermore, the duration of strain-specific immunity needed to be at least four years to explain the data actually observed. The presence and long duration of strain-specific immunity that the models suggest imply that humans, once infected, are highly unlikely to acquire a subsequent infection caused by the same strain of B. burgdorferi.

The fact that the strain-specific immunity is lasting has implications for vaccine design. Dustin Brisson, PhD, an assistant professor and senior author of the study, said, “If you could make a vaccine that covers several of these strains, you could substantially reduce the probability of infection in vaccinated people. The vaccine could last several years, perhaps requiring a booster once every several years.” The study was published in the April 2014 issue of the journal Infection and Immunity.

Related Links:

University of Pennsylvania


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.